Abstract
Patients taking amitriptyline (AMT) have an increased risk of sudden cardiac death, yet the mechanism for AMT's proarrhythmic effects remains incompletely understood. Here, we hypothesize that AMT activates cardiac ryanodine channels (RyR2), causing premature Ca2+ release from the sarcoplasmic reticulum (SR), a mechanism identified by genetic studies as a cause of ventricular arrhythmias and sudden cardiac death. To test this hypothesis, we measured the effect of AMT on RyR2 channels from mice and sheep and on intact mouse cardiomyocytes loaded with the Ca2+ fluorescent indicator Fura-2 acetoxymethyl ester. AMT induced trains of long channel openings (bursts) with 60 to 90% of normal conductance in RyR2 channels incorporated in lipid bilayers. The [AMT], voltage, and open probability (Po) dependencies of burst frequency and duration indicated that AMT binds primarily to open RyR2 channels. AMT also activated RyR2 channels isolated from transgenic mice lacking cardiac calsequestrin. Reducing RyR2 Po by increasing cytoplasmic [Mg2+] significantly inhibited the AMT effect on RyR2 channels. Consistent with the single RyR2 channel data, AMT increased the rate of spontaneous Ca2+ releases and decreased the SR Ca2+ content in intact cardiomyocytes. Intracellular [AMT] were approximately 5-fold higher than extracellular [AMT], explaining AMT's higher potency in cardiomyocytes at clinically relevant concentrations (0.5-3 μM) compared with its effect in lipid bilayers (5-10 μM). Increasing extracellular [Mg2+] attenuated the effect of AMT in intact myocytes. We conclude that the heretofore unrecognized activation of RyR2 channels and increased SR Ca2+ leak may contribute to AMT's proarrhythmic and cardiotoxic effects, which may be counteracted by interventions that reduce RyR2 channel open probability.
Footnotes
-
This work was supported in part by National Institutes of Health grants HL88635 and HL71670 (to B.C.K.), by the American Heart Association Established Investigator Award0840071N (to B.C.K.), by the Australian Research Council grant DP0557780 (to D.R.L.), by an infrastructure grant from NSW Health through Hunter Medical Research Institute (to D.R.L.) and by a Senior Brawn Fellowship from the University of Newcastle (to D.R.L.).
-
This work was presented in abstract form at the 2007 American Heart Association annual scientific meeting [Chopra N, Laver D, Watanabe H, Menon U, Stein CM, and Knollmann BC (2007) Amitriptyline activates cardiac ryanodine receptors independently of its action on cardiac calsequestrin—role for amitriptyline linked sudden cardiac death. Circulation116:II-84] and the 2008 Biophysics Society annual scientific meeting [Laver D, Chopra N, and Knollmann BC (2008) Mechanisms for amitriptyline activation of cardiac RyRs and SR Ca2+ release. Biophys J94:2120].
-
N.C. and D.L. contributed equally to this study.
-
ABBREVIATIONS: TCA, tricyclic antidepressant; SCD, sudden cardiac death; AMT, amitriptyline; SR, sarcoplasmic reticulum; RyR2, cardiac SR Ca2+ release channels; Casq2, cardiac calsequestrin; TES, N-tris [hydroxymethyl]methyl-2-aminoethanesulfonic acid; BAPTA, 1,2-bis(2-aminophenoxy)ethane-N,N,N′,N′-tetraacetic acid; Po, open probability; AM, acetoxymethyl ester; SCR, spontaneous Ca2+ release; LC/MS/MS, liquid chromatography/tandem mass spectrometry; IMP, imipramine; τo, open time; τc, closed time; I, current.
- Received August 19, 2008.
- Accepted October 8, 2008.
- The American Society for Pharmacology and Experimental Therapeutics
MolPharm articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|